AZ-TITAN

A Phase 1, open-label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD5492 following administration of a single ascending dose and dose-escalation in adult participants

Condition studied : Systemic lupus erythematosus, Idiopathic inflammatory myopathies

Treatment : Repeated injections of AZD5492

Inclusion criteria :

Systemic lupus erythematosus
– Have moderate to severe active disease
– Must not have responded to (or tolerated) three or more treatments for the condition
Idiopathic inflammatory myopathy
– Must have active severe disease
– Must not have responded to (or tolerated) two or more treatments for the condition
Rheumatoid arthritis
– Swollen joints ≥ 6; painful joints ≥ 6
– Have active disease
– Have not responded to (or have not tolerated) two or more biologic or targeted therapies for the disease

Exclusion criteria :

– Active lupus nephritis
– Inclusion body myositis
– Active or past lupus-related neurological involvement
– Severe pulmonary involvement
– Use of certain immunosuppressive treatments

Sponsor : Astrazeneca

Principal Investigator : Pr. Christian Jorgensen

N° : NCT06916806 | A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. | ClinicalTrials.gov

Investigator

Pr. Christian Jorgensen

Director